
The study analyzed 684 patients from European trials and found high p53 expression combined with MIPI-c predicts poor prognosis. The high-risk group showed significantly shorter median failure-free survival (FFS) and overall survival (OS) compared to the low-risk group. Validation cohorts supported findings. A current treatment may not be sufficient for high-risk patients, prompting the need for innovative approaches
Like
Save
Share